Introduction
Aortic stenosis (AS) is the most prevalent heart valve disease in the Western World and is associated with a poor prognosis after onset of symptoms. [1] [2] [3] After its introduction in 2002, transcatheter aortic valve replacement (TAVR) has become an alternative to surgical aortic valve replacement (SAVR) in certain high-risk patients with severe aortic valve stenosis. 4, 5 Randomised trials have shown beneficial effects on clinical outcomes and survival after TAVR compared with best medical treatment in patients deemed ineligible for SAVR (PARTNER B, CoreValve US ER), 6, 7 and similar or improved survival rate for high-risk patients undergoing TAVR compared with SAVR (PARTNER A, CoreValve US HR). 8, 9 In recent years, there has been a trend to treat lower risk patients, and observational studies have demonstrated acceptable mortality outcomes in low-and intermediate-risk patients. [10] [11] [12] [13] [14] The Nordic Aortic Intervention (NOTION) trial was the first randomized all-comers trial, which showed similar clinical outcomes and survival after TAVR with a self-expanding prosthesis vs SAVR in a lower risk patient population with severe aortic valve stenosis. 15 Most of the people with severe aortic stenosis develop a compensated left ventricular hypertrophy to counteract the increased resistance (afterload) posed by the stenotic aortic valve. In the beginning, left ventricular systolic function is preserved. However, if the stenosis is left untreated, the systolic function may suffer and eventually worsen. Restoring the aortic valve function by treatment with either SAVR or TAVR will increase the aortic valve area, lower aortic valve gradients, reverse left ventricular hypertrophy, decrease the amount of dyspnoea, and reduce mortality. 6, 8 However, there are differences between the two treatment regimes. Treatment with TAVR usually yields larger aortic valve area than SAVR, but is also related to more paravalvular leakage (PVL) and conduction abnormalities requiring pacemaker implantation. Moreover, differences between the implantation process between SAVR and TAVR may in itself lead to differences in aortic valve function and hemodynamics as well as left ventricle (LV) dimension and function. The purpose of this echocardiographic study was to compare left ventricular remodelling in patients with severe aortic valve stenosis treated with either TAVR or SAVR in the NOTION-trial.
Methods
In the NOTION-trial, a total of 280 patients with severe aortic stenosis, but with no need for coronary revascularization, were randomized 1:1 to TAVR with a self-expanding prosthesis (CoreValve, Medtronic) vs. SAVR (either a native porcine or a bovine pericardial prosthesis) at three Nordic centres, two in Denmark and one in Sweden of which 232 patients were randomized at our institution (Rigshospitalet, University of Copenhagen, Denmark). The trial was conducted according to the principles of the Declaration of Helsinki, and the regional ethical review board at each site approved the protocol. All patients provided written informed consent. Transthoracic echocardiographic studies were performed at baseline as well as 3 and 12 months post-procedure. All echocardiographic studies (iE33 equipped with an s5-1 probe, Philips, The Netherlands) were performed in accordance to a pre-defined protocol by experienced technicians at Rigshospitalet. To ensure uniformity of data, all echocardiographic studies were re-analysed by a single experienced investigator using Xcelera v3.3L1 and Q-lab software v9 (Philips, The Netherlands).
Aortic valve function
Aortic valve area (AVA) was estimated with the use of the continuity equation: left ventricular outflow tract (LVOT) was measured as the inner diameter $5 mm below the aortic annulus during mid-systole in parasternal long axis view (PLAX). Pulsed wave (PW) Doppler and continuous wave (CW) Doppler were measured in apical 5-chamber view at the same level, where the LVOT measurement was made, and through the aortic valve, respectively. To avoid wrong estimates of LVOT by prosthesis shadowing, we used the baseline LVOT measurements for the calculation of AVA at the 3 and 12 months studies.
In accordance with the VARC-II criteria, 16 we used an integrated multi-view assessment to assess paravalvular leakage (PVL) in TAVR patients with special emphasis on the parasternal short-axis view(s) of the aortic valve using a 4-grade scheme as follows: (0) none/trace = no regurgitant color flow/pinpoint jet in aortic valve; (1) mild = jet arc length is <10% of the prosthesis circumference; (2) moderate = jet arc length is 10% to 30% of the prosthesis circumference; (3) severe = jet arc length is >30% of the prosthesis circumference. Prosthesis-patient mismatch (PPM) was calculated as the AVA/BSA (body surface area) as originally described by Rahimtoola in 1978 17 and as later modified by Pibarot. 18 There was no PPM when indexed AVA 
Statistics
Demographic data are shown as mean ± SD, whereas echocardiographic and hemodynamic data are shown as mean ± SEM. Comparisons of continuous variables between the SAVR and TAVR group were done using Student's t-test. Categorical variables were compared using the v 2 -test. Intra-observer variability was estimated with Bland-Altman plots. Linearmixed model analysis with repeated measurements analysis and unstructured covariance pattern was used to evaluate changes in LVEF, indexed LV mass and EDV over time, while correcting for baseline characteristics (sex and age) and factors such as the presence of PPM, PVL and a pacemaker at follow-up, which might have an influence on these measures. The status of PPM, PVL, and pacemaker was entered into the model in binary format (no PPM/PPM, no PVL/PVL, and no pacemaker/pacemaker). P values < 0.05 were considered statistically significant. The statistical analyses were performed using SPSS version 21 and SAS software version 9. 4 .
Results
About 232 patients were included in the NOTION trial at our institution. In the intention to treated group, 120 were randomized to TAVR and 112 to SAVR. Of the patients randomized to TAVR, two patients were converted to SAVR and one patient died before the procedure. Of the patients randomized to SAVR, one patient was converted to TAVR, one patient was converted to an apico-aortic conduit because of porcelain aorta, and one patient died before the procedure. The mean age of the patients was 79 years and 55% being males. The mean STS-score was 3.1%, placing these patients in the low-risk group. In general, the patients had a low burden of comorbidities, such as diabetes mellitus, nephropathy defined by creatinine level > 2 mg/dl, prior cerebrovascular disease including
transient ischemic attack (TIA) and stroke, chronic pulmonary lung disease and former acute myocardial infarction ( Table 1) . However, more than 70% of the patients had hypertension and about onefourth of the patients had atrial fibrillation or atrial flutter ( Table 1) . The TAVR procedures were performed by femoral access in 96% of the patients and by subclavian access in the remaining 4%. Seventy% of SAVR patients received a native porcine (either Mosaic Ultra Porcine Heart Valve, Medtronic; Tissue heart valve, Medtronic; or Epic, St. Jude Medical) and 30% a bovine pericardial prosthesis (Trifecta, St. Jude Medical). Table 2 presents echocardiographic and hemodynamic data at baseline, 3 and 12 months after SAVR and TAVR.
To estimate intra-observer variability of IVSd, LVIDd and LVPWd, used in the LV mass calculation, these parameters were re-analysed consecutively in 10 SAVR and 10 TAVR patients at baseline, 3 and 12 months (n = 60). There was a good reliability of repeated measurements by the same analyser as shown by the Bland-Altman plots for these parameters (Supplementary data online, Figure S1 ).
Changes in aortic valve area and prosthesis-patient mismatch
In the SAVR group, AVA increased from 0.78 ± 0.02 cm 2 at baseline to 1.52 ± 0.05 cm 2 at 3 months, and 1.44 ± 0.04 cm 2 at 12 months (P < 0.0001) post-procedure. In the TAVR group, AVA increased from 0.74 ± 0.02 cm 2 at baseline to 1.83 ± 0.04 cm 2 at 3 months and 1.76 ± 0.05 cm 2 at 12 months (P < 0.0001) post-procedure ( Figure 1 and Table 2 ). The increase in AVA was statistically significant (P < 0.0001) larger in the TAVR compared with the SAVR group at both 3 and 12 months post-procedure ( Table 2) . PPM was observed with different frequencies in the SAVR and TAVR group. In the SAVR group, 32.3% had no PPM, 31.2% had moderate PPM, There are no statistically significant differences between the groups on any baseline characteristics. ) with 95% CI measured at baseline, 3 and 12 months after SAVR and TAVR group (*P < 0.01 and **P < 0.01 between SAVR vs. TAVR).
Differences in left ventricular remodelling in patients treated with TAVR or SAVR 
Changes in left ventricular systolic function
LVEF showed a small but statistically significant improvement after SAVR, where LVEF increased from 54.2 ± 1.1% at baseline to 55.4 ± 1.0% at 3 months and 57.3 ± 0.9% at 12 months (P < 0.01, baseline vs. 12 months). However, patients who underwent TAVR did not show any improvement in LVEF. The increase in LVEF from baseline to 12 months was statistically significant larger (3.5 ± 1.2% vs. -1.5 ± 0.9%, P < 0.001) in the SAVR group compared with the TAVR group ( Table 2) .
Changes in left ventricular mass and dimensions
LV remodelling was observed in both the SAVR and the TAVR group. In the SAVR group, indexed LV mass regressed from 117. Table 2) . The reduction in indexed LV mass was the largest in the SAVR group (P < 0.001) (17.5% vs. 7 .2% for SAVR and TAVR, respectively) ( Figure 2 and Table 2 ). RWT decreased after both SAVR and TAVR ( Table 2 ). In the SAVR group, RWT showed a statistically significant decrease from 0.54 ± 0.02 at baseline to 0.51 ± 0.02 at 12 months post-procedure (baseline vs. 12 months, P = 0.03). In the TAVR group, RWT also significantly decreased from 0.56 ± 0.01 at baseline to 0.50 ± 0.01 at 3 months and 0.51 ± 0.01 at 12 months post-procedure (baseline vs. 12 months, P < 0.0001, Table 2) .
To show the impact of SAVR vs. TAVR on left ventricular shape remodelling, LV mass indexed was plotted against RWT before and 12 months after the procedures. Before both procedures the left ventricles were 'concentric hypertrophic' in shape. Because indexed LV mass decreased more after SAVR compared TAVR, the left ventricles transformed into a 'concentric remodelling' shape after SAVR, but remained 'concentric hypertrophic' after TAVR (Figure 3) .
Differences between LV mass regression between the SAVR and the TAVR group could not be explained by different changes in left ventricular wall thickness, because IVSd and LVPWd decreased similarly after the procedures in both groups (Table 2, P = NS). However, differences in LV mass regression were due to different changes in LVIDd and EDV in the two groups ( Table 2 ). In the SAVR group, EDV decreased from 89 ± 3 ml at baseline to 78 ± 3 ml at 3 months and 73 ± 2 ml at 12 months (P < 0.0001) post-procedure. On the contrary, EDV increased from 87 ± 3 ml at baseline to 93 ± 4 ml at 3 months and 96 ± 4 ml at 12 months (p < 0.01) post-procedure in the TAVR group ( Table 2) . The changes in EDV (EDV at 3 or ) with 95% CI from baseline to 3 and 12 months after SAVR and TAVR (*P < 0.01 and **P < 0.001 between SAVR vs. TAVR).
Figure 4
Changes in EDV (ml) with 95% CI from baseline to 3 and 12 months after SAVR and TAVR (*P < 0.01 and **P < 0.01 between SAVR vs. TAVR).
Differences in left ventricular remodelling in patients treated with TAVR or SAVR
12 months-EDV at baseline) were statistically significant different between the two groups (P < 0.0001) (Figure 4) .
Occurrence of paravalvular and mitral regurgitation and pacing
PVL was much more frequent after TAVR compared with SAVR. At 12 months, 27% of the TAVR patients had none/trace PVL, 59% had mild PVL, and 14% had moderate/severe PVL. Among the SAVR patients 82% had none/trace PVL, 18% had mild PVL, and none had moderate/severe PVL ( Table 3) .
The degree of mitral regurgitation (MR) was unchanged in the TAVR group pre-and post-procedure (P = NS), but there was a slight reduction in mild/moderate MR in the SAVR group from 40.7% at baseline to 23.5% at 12 months post-procedure (P < 0.01) ( Table 3) . None of the patients in the study received mitral valve repair or replacement during the study period.
The pacemaker implantation frequency in this study was much higher after TAVR (at 12 months, 40% had a pacemaker in the TAVR group as compared with 5% in the SAVR group). Four patients in the SAVR group and five patients in TAVR group already had a pacemaker before enrolment into the study. After the aortic valve procedures, two patients had a pacemaker implanted in the SAVR group compared to 40 patients in the TAVR group. The patients had either a DDD or VVI-pacemaker. Only one patient in the TAVR group had a BIV-ICD, which was implanted before the study.
The effect of paravalvular leakage, prosthesis-patient mismatch and pacing on left ventricular systolic function, mass and volume
Because there were significant differences between the frequencies of PPM, PVL, and pacemakers, these factors may account for the differences observed in LVEF, indexed LV mass and EDV between the two treatment regimes. To evaluate the effect of PPM, PVL and the presence of a pacemaker on LVEF, indexed LV mass and EDV, a linear-mixed model, corrected for sex and age, was built.
This model showed that the presence of PPM (P = 0.50), PVL (P = 0.42), and a pacemaker (P = 0.12) had no effect on LVEF.
Indexed LV mass was not affected by the presence of PPM (P = 0.99), PVL (P = 0.21), and a pacemaker (P = 0.07) either.
However, the presence of PPM (P = 0.04), PVL (P < 0.01), and a pacemaker (P < 0.01) were statistically significantly associated with an increase in EDV.
Discussion
In concordance with other studies, the use of a self-expandable CoreValve prosthesis for TAVR in this study resulted in a larger AVA and less PPM compared with SAVR. 20, 21 Similar findings as ours were shown in the PARTNER trial, where a larger LV mass regression was observed in patients receiving SAVR compared with TAVR, a difference that was observed for up to 1 year post-procedure. 9 The larger AVA after TAVR can be explained by the fact, that the CoreValve prosthesis is designed with a trileaflet porcine pericardial valve mounted in supra-annular position in the nitinol frame. This feature contributes to the increased AVA compared with surgical aortic prostheses, which have a wider sewing ring. The amount of PPM after TAVR and SAVR in this study was comparable with that of the PARTNER A trial. 20 Despite TAVR being better at improving AVA compared with SAVR, LV mass regression was more pronounced after SAVR. The reason for reduced LV mass regression after TAVR was not because of a smaller decrease in LV wall thickness, but because of an increase in LVIDd and EDV at 12-month follow-up in contrast to a reduction of LVIDd and EDV after SAVR. Moreover, the left ventricle changed from a concentric hypertrophic (pressure overloaded) shape to a more normal shape after SAVR, whereas the left ventricular shape in the patients undergoing TAVR remained concentric hypertrophic, thus demonstrating less left ventricular remodelling after TAVR. Due to the very different nature of the surgical and transcatheter treatment, there could be a number of factors that could account for the differences in the changes in LVEF, indexed LV mass, and EDV after SAVR and TAVR. At first, PPM indicates that the aortic valve prosthesis is too small relative to a person's size and has been shown to be related to poor outcome, especially in patients with reduced LV function. 22 PPM has also been related to a poorer LV mass regression after aortic valve replacement. In patients with severe aortic stenosis receiving TAVR, the presence of PPM was associated with less LV mass regression. 23 However, not all studies have shown this association. In PARTNER A trial, Piparot et al. showed a decreased LV mass regression in SAVR patients with PPM, but not in patients receiving TAVR with PPM. They suggested that this difference could be caused a greater amount of PVL in the TAVR group, which might counteract the LV mass regression. 21 Furthermore, Bobiarski et al. 24 compared two different surgical aortic valves prostheses for treatment of patients with severe aortic stenosis and showed that a larger AVA did not translated into a better LV mass regression. Our linear mixed model analysis showed that PPM had no effects on LVEF and indexed LV mass, but was associated with an increase in EDV. Second, a large proportion (40%) of patients in the TAVR group was treated with a pacemaker resulting in right ventricular pacing, which is known to affect LV remodelling and function. 25 The high pacemaker implantation frequency in the TAVR group might be specifically related to the design of the self-expandable CoreValve prosthesis with a frame protruding and flaring into the LVOT, which may cause compression of the conduction system. Implantation with other types of stented aortic valve prostheses, e.g. implantation with the balloon-expandable SAPIEN (Edwards Life-sciences) used in the PARTNER trial showed less pacemaker requirement compared to CoreValve used in our study. 9 , 0 Our linear-mixed model analysis
showed that the presence of a pacemaker was associated in an increase in EDV. However, it did not seem to affect LVEF or indexed LV mass. Third, there was a major difference in the amount of PVL between the TAVR and SAVR groups in the NOTION trial. Seventy-two percent of the patients receiving TAVR had PVL at 12 months as compared with only 18% in the SAVR group. Moreover, patients receiving SAVR only had mild PVL, while moderate and severe PVL was also observed after TAVR (Table 3) . This rate was comparable with other studies of TAVR, 26 but higher than other randomized trials of TAVR vs. SAVR. 6, 8 The mechanism for the aortic regurgitation is mainly paravalvular and is related to several anatomical factors (e.g. annular size, shape, degree, and distribution of calcification) 27 and the type of prosthesis used, with more PVL after self-expandable compared with balloon-expandable prostheses. 28, 29 In the NOTION trial, computed tomography (CT) scans and 3D-echocardiography was not used systematically for annular sizing, because it was not standard practice at the time when the NOTION trial was conducted, potentially leading to valve-under-sizing and therefore more PVL. In this study, patients receiving TAVR, but not after SAVR, had a statistically significant fall in diastolic blood pressure ( Table 2 , P < 0.001), which may be explained by more PVL after TAVR. PVL causes volume overload of the left ventricle and possible dilatation. While some studies have shown that the degree of PVL in TAVR treated patients can be related to mortality and hospitalization, 26, 30 others have not found this relationship. 8 The linear-mixed model analysis showed that PVL was associated with an increase in EDV, but had no significant effects on indexed LV mass and LVEF.
In summary, the main finding of this study was that although AVA improved more after TAVR compared to SAVR, LV mass regression was more pronounced after SAVR. This difference is explained by a decrease in EDV in the SAVR group in contrast to an increase in EDV in the TAVR group, because LV wall thickness decreased similarly in both groups after the procedures. Presence of PVL and a pacemaker, which was much more frequent in TAVR, were associated with an increase in EDV, which may explain the diminished LV mass regression observed after TAVR.
Limitations
As this is a single centre study at Rigshospitalet, not all 280 patients in NOTION-trial were included in this study.
Conclusion
Patients undergoing SAVR had a larger LV mass regression at 1 year compared with patients undergoing TAVR. The differences were associated with the increased frequency of PVL and pacemakers in the TAVR group. Present efforts to decrease the incidence of PVL and pacemaker implantations related to TAVR, therefore, seem important to optimize the long-term results after TAVR.
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Supplementary data are available at European Heart JournalCardiovascular Imaging online.
